There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Esperion (ESPR – Research Report) and Beam Therapeutics (BEAM – Research Report) with bullish sentiments.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ESPR:
- Esperion Reports First Quarter 2024 Financial Results
- Esperion to Participate in Upcoming May Investor Conferences
- Esperion presents new data from CLEAR Outcomes at ACC.24
- Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
- Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
